Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 4.57% and Operating profit at -26.36% over the last 5 years
3
Positive results in Sep 25
4
With ROE of -0.06%, it has a risky valuation with a 12.36 Price to Book Value
5
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,590 Million (Mid Cap)
78.00
NA
0.00%
-0.25
7.24%
5.63
Revenue and Profits:
Net Sales:
140 Million
(Quarterly Results - Mar 2026)
Net Profit:
27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.4%
0%
3.4%
6 Months
11.25%
0%
11.25%
1 Year
84.08%
0%
84.08%
2 Years
112.12%
0%
112.12%
3 Years
75.11%
0%
75.11%
4 Years
241.45%
0%
241.45%
5 Years
62.58%
0%
62.58%
Sino Medical Sciences Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.80%
EBIT Growth (5y)
29.84%
EBIT to Interest (avg)
-61.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.43
Tax Ratio
50.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
78
Industry P/E
Price to Book Value
5.63
EV to EBIT
69.06
EV to EBITDA
36.54
EV to Capital Employed
7.19
EV to Sales
9.46
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
10.41%
ROE (Latest)
7.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
139.70
161.60
-13.55%
Operating Profit (PBDIT) excl Other Income
28.70
49.90
-42.48%
Interest
1.00
1.20
-16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
27.10
26.70
1.50%
Operating Profit Margin (Excl OI)
205.70%
173.00%
3.27%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -13.55% vs 30.96% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 1.50% vs 251.32% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
519.50
455.10
14.15%
Operating Profit (PBDIT) excl Other Income
141.60
57.40
146.69%
Interest
5.30
5.80
-8.62%
Exceptional Items
0.20
0.00
Consolidate Net Profit
47.50
-3.90
1,317.95%
Operating Profit Margin (Excl OI)
92.10%
-99.20%
19.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.15% vs 33.30% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 1,317.95% vs 91.01% in Dec 2024
About Sino Medical Sciences Technology, Inc. 
Sino Medical Sciences Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






